Plantibodies produces plant-based monoclonal antibodies using synthetic and molecular biology techniques to target life-threatening diseases such as cancers, neurodegenerative disorders, and autoimmune conditions. This approach enables the generation of stable antibodies from plants, providing a potential therapeutic solution for patients facing these serious health challenges.
Funding
$970K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current biologic immunotherapies, administered via injection, are inefficient for treating gastrointestinal diseases, with less than 5% of the dose reaching the gut. Systemic absorption of the injected dose often leads to significant side effects, high treatment expenses, and less-than-ideal patient outcomes.
Solution
Plantibodies is developing orally delivered biologic therapies precisely targeted to the colon, designed to improve outcomes for patients with chronic gastrointestinal diseases. Their platform enables local action within the GI tract while minimizing systemic exposure, potentially enhancing patient quality of life, reducing toxicity and treatment burden, and expanding access through convenient, scalable therapies. By converting existing injectable biologics into targeted oral treatments, Plantibodies aims to extend the life and reach of these therapies while offering a safer, more effective delivery method. The company leverages synthetic and molecular biology techniques to produce plant-based monoclonal antibodies.
Target Audience
The primary target audience includes patients with chronic gastrointestinal diseases and the healthcare providers who treat them.
Features
- Orally delivered biologics for targeted action in the colon
- Minimal systemic exposure, reducing side effects
- Plant-based monoclonal antibody production
- Conversion of injectable biologics into oral therapies